8-K
filed April 21, 2026, 7:59 PM ET
CIK 0001845459
debt
confidence high
sentiment neutral
materiality 0.75
NKGen Biotech, Inc.: debt financing — NKGen Biotech enters $39.9M secured convertible loan with AlpineBrook; conversion at $0.08/share
NKGen Biotech, Inc.
- Loan of $39,922,134 refinances existing notes and provides $350,000 new cash for operations.
- Convertible at $0.08 per share; 12% interest, one-year maturity, with 20% change-of-control premium.
- Lender issued warrant for up to 3x principal/conversion price shares at $0.08, ten-year term.
- Company must increase authorized shares to allow conversion/warrant exercise; board size fixed at nine.
- NKGen has limited cash and continues seeking additional funding; security includes IP and 65% of NKGen Korea.
Key facts
Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
NKGen Biotech, Inc. incurred convertible notes of $39,922,134.22 with AlpineBrook Capital GP I Limited at 12% per annum maturing one-year anniversary of the closing date.
- Instrument
- convertible notes
- Principal
- $39,922,134.22
- Counterparty
- AlpineBrook Capital GP I Limited
- Rate
- 12% per annum
- Maturity
- one-year anniversary of the closing date
- Event
- incurrence
Exact text from the filing
Capital GP I Limited (the “Lender”). Background Pursuant to the Loan Agreement, the Lender agreed to extend a secured convertible loan in the aggregate principal amount of $39,922,134.22 (the “Convertible Loan”) to the Borrowers. The Convertible Loan refinances and replaces the following existing indebtedness of the Borrowers to the Lender and East West Bank
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
NKGen Biotech, Inc. issued warrant to AlpineBrook Capital GP I Limited.
- Security
- warrant
- Purchaser
- AlpineBrook Capital GP I Limited
Exact text from the filing
the Company agreed to issue to the Lender the following securities (the “Securities”) without registration under the Securities Act of 1933, as amended (the “Securities Act”): (a) 11,807,380 shares of Common Stock (the Consideration Shares), to be issued in five installments commencing on the five-month anniversary of the closing date; (b) the Note, which is convertible into shares of Common Stock at a conversion price of $0.08 per share, subject to adjustment; and (c) the Warrant, which is exercisable for shares of Common Stock at an exercise price of $0.08 per share, subject to adjustment.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
NKGen Biotech, Inc. issued convertible note to AlpineBrook Capital GP I Limited.
- Security
- convertible note
- Purchaser
- AlpineBrook Capital GP I Limited
Exact text from the filing
the Company agreed to issue to the Lender the following securities (the “Securities”) without registration under the Securities Act of 1933, as amended (the “Securities Act”): (a) 11,807,380 shares of Common Stock (the Consideration Shares), to be issued in five installments commencing on the five-month anniversary of the closing date; (b) the Note, which is convertible into shares of Common Stock at a conversion price of $0.08 per share, subject to adjustment; and (c) the Warrant, which is exercisable for shares of Common Stock at an exercise price of $0.08 per share, subject to adjustment.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
NKGen Biotech, Inc. issued 11,807,380 shares of Common Stock of common stock to AlpineBrook Capital GP I Limited.
- Security
- common stock
- Shares
- 11,807,380 shares of Common Stock
- Purchaser
- AlpineBrook Capital GP I Limited
Exact text from the filing
the Company agreed to issue to the Lender the following securities (the “Securities”) without registration under the Securities Act of 1933, as amended (the “Securities Act”): (a) 11,807,380 shares of Common Stock (the Consideration Shares), to be issued in five installments commencing on the five-month anniversary of the closing date; (b) the Note, which is convertible into shares of Common Stock at a conversion price of $0.08 per share, subject to adjustment; and (c) the Warrant, which is exercisable for shares of Common Stock at an exercise price of $0.08 per share, subject to adjustment.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
NKGen Biotech, Inc.: Amended Bylaws Section 4.1 to set maximum authorized number of directors at nine, changing from no specified number (effective 2026-04-15).
- Change
- bylaw amendment
- Effective
- 2026-04-15
Exact text from the filing
The Bylaws Amendment amends and restates Section 4.1 of the Amended and Restated Bylaws of the Company (the “Bylaws”) to provide that the maximum authorized number of directors shall be nine (9).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
NKGen Biotech, Inc. entered into Secured Convertible Loan Agreement with AlpineBrook Capital GP I Limited valued at $39,922,134.22 (effective 2026-04-15).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- AlpineBrook Capital GP I Limited
- Value
- $39,922,134.22
- Effective
- 2026-04-15
Exact text from the filing
“NKGen OpCo,” and together with the Company, the “Borrowers”), entered into a Secured Convertible Loan Agreement (the “Loan Agreement”) with AlpineBrook Capital GP I Limited (the “Lender”).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.